Resources | NITAG RESOURCE CENTER

2024 ∙ Eliza Dryer, Shefer, Abigail, Shalini Desai, Lance Rodewald, Magdalena Bastias, Nathalie El Omeiri, Sidy Ndiaye, Kori Cook, Louise Henaff, Erin Kennedy

Development of a maturity assessment tool to evaluate and strengthen National Immunization Technical Advisory Groups (NITAGs)

2024 ∙ STIKO

Resolution on the STIKO recommendation for a standard vaccination against diseases caused by respiratory syncytial viruses (RSV) for persons ≥ 75 years of age and for the indication vaccination of persons aged 60 to 74 years with risk factors

2024 ∙ NACI

Statement on the prevention of respiratory syncytial virus disease in older adults

2024 ∙ SAGE

Smallpox and mpox (orthopoxviruses) vaccine position paper

2024 ∙ Fortier, L. M. Smith, K. L. Ina, J. G. Sinkler, M. A. Calcei, J. G. Salata, M. J. Gillespie, R. Voos, J. E.

Common characteristics of shoulder injury related to vaccine administration following COVID-19 vaccination: a comprehensive systematic review

2024 ∙ Qiu, J. Zhang, S. Feng, Y. Su, X. Cai, J. Chen, S. Liu, J. Huang, S. Huang, H. Zhu, S. Wen, H. Li, J. Yan, H. Diao, Z. Liang, X. Zeng, F.

Efficacy and safety of hepatitis B vaccine: an umbrella review of meta-analyses

2024 ∙ Li, C. Zhang, M. Karthijekan, K. Fu, X.

How nurses contribute to the elimination of hepatitis B? A systematic review and meta-analysis

2024 ∙ Yin, J. Zhang, L. Wang, C. Qin, C. Miao, M.

Immunogenicity and safety of ebolavirus vaccines in healthy adults: a systematic review and meta-analysis of randomized controlled trials

2024 ∙ ACIP

ACIP Evidence to Recommendations for Use of Protein Subunit RSV vaccines (GSK Arexvy or Pfizer Abrysvo) in All Adults Aged ≥75 years and in Adults Aged 60–74 at Increased Risk of Severe RSV Disease

2024 ∙ ACIP

ACIP Evidence to Recommendations for Use of Moderna RSV Vaccine (mResvia) in All Adults Aged ≥75 years and in Adults Aged 60–74 at Increased Risk of Severe RSV Disease